Skip to main content
. 2019 Feb 10;2019:3561501. doi: 10.1155/2019/3561501

Table 2.

Multivariate predictors of chemotherapy receipt in nonmetastatic uterine LMS.

Variable OR 95% CI P
Year of diagnosis      
 Per year increase 1.16 1.13–1.20 <0.0001

Age at diagnosis, y      
 18–39 Ref    
 40–49 0.93 0.67–1.31 0.6927
 50–64 0.93 0.67–1.29 0.6537
 65+ 0.60 0.38–0.94 0.0264

Race      
 White Ref    
 African American 0.80 0.63–1.02 0.0727
 Other 1.09 0.78–1.53 0.5965

Hispanic      
 Yes 1.34 0.94–1.91 0.1112
 No Ref    

Comorbidities (Charlson/Deyo score)      
 0 Ref    
 1 0.93 0.73–1.18 0.5332
 2 0.72 0.37–1.41 0.3381

Insurance status      
 Private Ref    
 Medicare 0.59 0.42–0.84 0.0030
 Medicaid 1.06 0.77–1.48 0.7062
 None 0.92 0.64–1.30 0.6265
 Other government 2.42 1.04–5.61 0.0400

Education (% no high school diploma)      
 ≥21 0.68 0.48–0.97 0.0354
 13–20.9 0.58 0.43–0.79 0.0005
 7–12.9 0.86 0.68–1.09 0.2143
 <7 Ref    

Median household income ($)      
 <38,000 1.49 1.04–2.13 0.0282
 38,000–47,999 1.42 1.05–1.92 0.0239
 48,000–62,999 1.37 1.07–1.75 0.0117
 >63,000 Ref    

Location of patient      
 Large metropolitan Ref    
 Small metropolitan 0.92 0.73–1.15 0.4570
 Suburban 1.00 0.73–1.39 0.9764
 Rural 0.69 0.43–1.10 0.1146

Hospital volume (cases per year)      
 0.09 Ref    
 0.18–0.27 1.00 0.62–1.61 0.9964
 0.36–0.55 1.18 0.74–1.87 0.4912
 0.64–7.27 1.27 0.82–1.98 0.2812

Regional lymph nodes positive      
 Yes 3.83 1.81–8.09 0.0004
 No Ref    

Stage      
 I 0.32 0.25–0.41 <0.0001
 II 0.38 0.26–0.56 <0.0001
 III Ref    

Hormone therapy      
 Yes 0.72 0.30–1.70 0.4473
 No Ref    

Radiation      
 Yes 1.45 1.17–1.79 0.0006
 No Ref    

Oophorectomy      
 Yes 0.92 0.72–1.19 0.5395
 No Ref